One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
-
Patent number: 8703186Abstract: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist.Type: GrantFiled: April 16, 2013Date of Patent: April 22, 2014Assignee: Elite Laboratories, Inc.Inventor: Atul M. Mehta
-
Patent number: 8703949Abstract: The present invention provides processes for the preparation of N-alkyl morphinans without the isolation of nor-morphinan intermediates. In particular, the invention provides tandem hydrolysis/alkylation reactions for the synthesis of N-alkyl morphinans.Type: GrantFiled: August 3, 2011Date of Patent: April 22, 2014Assignee: Mallinckrodt LLCInventors: Subo Liao, Peter X. Wang, David W. Berberich, Douglas C. Miller
-
Patent number: 8703177Abstract: The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized.Type: GrantFiled: August 20, 2012Date of Patent: April 22, 2014Assignee: BioDelivery Sciences International, Inc.Inventors: Andrew Finn, Niraj Vasisht
-
Patent number: 8703791Abstract: The invention provides 3-carboxypropyl-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: June 19, 2013Date of Patent: April 22, 2014Assignee: Theravance, Inc.Inventors: Sean G. Trapp, Michael R. Leadbetter, Daniel D. Long, John R. Jacobsen, Priscilla Van Dyke
-
Publication number: 20140107146Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.Type: ApplicationFiled: December 20, 2013Publication date: April 17, 2014Applicant: Purdue PharmaInventors: Frank S. CARUSO, Huai-Hung KAO
-
Publication number: 20140105987Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.Type: ApplicationFiled: October 15, 2013Publication date: April 17, 2014Applicant: COLLEGIUM PHARMACEUTICAL, INC.Inventors: Roman V. RARIY, Alison B. FLEMING, Jane HIRSH, Alexander M. KLIBANOV
-
Publication number: 20140107145Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.Type: ApplicationFiled: December 18, 2013Publication date: April 17, 2014Applicant: AEGIS THERAPEUTICS, INC.Inventor: Edward T. Maggio
-
Publication number: 20140105977Abstract: The present disclosure provides extended release pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state.Type: ApplicationFiled: December 18, 2013Publication date: April 17, 2014Applicant: MALLINCKRODT LLCInventors: KRISHNA R. DEVARAKONDA, MICHAEL J. GIULIANI, VISHAL K. GUPTA, RALPH A. HEASLEY, SUSAN SHELBY
-
Publication number: 20140107143Abstract: Compounds of formulas: are disclosed. The compounds are useful for ameliorating the side effects of therapeutic opiates.Type: ApplicationFiled: September 27, 2013Publication date: April 17, 2014Applicant: Rensselaer Polytechnic InstituteInventor: Mark P. WENTLAND
-
Publication number: 20140105830Abstract: The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.Type: ApplicationFiled: December 23, 2013Publication date: April 17, 2014Applicant: GRUENENTHAL GMBHInventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU MARIC
-
Publication number: 20140099376Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1.Type: ApplicationFiled: May 22, 2013Publication date: April 10, 2014Inventors: Christopher Breder, Benjamin Oshlack, Curtis Wright
-
Publication number: 20140099369Abstract: Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.Type: ApplicationFiled: October 4, 2013Publication date: April 10, 2014Applicant: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Curtis Wright, J.David Haddox
-
Publication number: 20140093559Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.Type: ApplicationFiled: November 1, 2013Publication date: April 3, 2014Applicant: GRUNENTHAL GMBHInventors: JOHANNES BARTHOLOMAEUS, HEINRICH KUGELMANN
-
Publication number: 20140094481Abstract: Tamper resistant controlled release formulations.Type: ApplicationFiled: April 19, 2013Publication date: April 3, 2014Applicant: Euro-Celtique S.A.Inventor: Euro-Celtique S.A.
-
Publication number: 20140094482Abstract: A method of inhibiting hyperphosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system a FLNA-binding effective amount of a FLNA-binding benzazocine-ring compound or a pharmaceutically acceptable salt thereof such as a) an opioid receptor antagonist compound or b) a mixed opioid receptor agonist and antagonist (agonist/antagonist) compound, c) an opioid receptor agonist compound or d) an enantiomer of an opioid receptor interacting compound, that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1. The administered compound preferably contains at least four of the six pharmacophores of FIGS. 5-10.Type: ApplicationFiled: August 15, 2013Publication date: April 3, 2014Inventors: George B. Thornton, Hoau-Yan Wang, Lindsay Burns Barbier, Michael S. Zamloot
-
Publication number: 20140093569Abstract: A pharmaceutical composition for controlled release of an active substance is provided. The active substance is released into an aqueous medium by erosion of at least one surface of the composition. The composition comprises i) a matrix comprising a) polymer or a mixture of polymers, b) an active substance and, optionally, c) one or more pharmaceutically acceptable excipients, and ii) a coating.Type: ApplicationFiled: August 23, 2013Publication date: April 3, 2014Applicant: EGALET LTD.Inventors: Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Christine Andersen
-
Patent number: 8685996Abstract: Disclosed are methods for making aldehydes and ketones comprising allowing the corresponding primary or secondary alcohol to react in the presence of trichoroisocyanuric acid, a compound of formula R1SR2 and a base. In one embodiment, the alcohol is a compound of formula (I): wherein R3 is a protecting group. Also disclosed are methods for making 3-O-protected morphine dienol carboxylates comprising allowing a compound of formula (I) to oxidize in the presence of a chlorine-containing compound and a compound of formula R1SR2; and allowing the product of the oxidation step to react with an acylating agent.Type: GrantFiled: May 15, 2012Date of Patent: April 1, 2014Assignee: Purdue Pharma L.P.Inventor: Andreas Stumpf
-
Patent number: 8685994Abstract: Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of celecoxib and/or at least one pharmaceutically acceptable salt thereof and oxycodone and/or at least one pharmaceutically acceptable salt thereof, said two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising orally administering to the patient an oral dosage form comprising two analgesic compounds consisting of celecoxib and/or at least one pharmaceutically acceptable salt thereof and oxycodone and/or at least one pharmaceutically acceptable salt thereof, said two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient.Type: GrantFiled: January 26, 2007Date of Patent: April 1, 2014Assignee: Purdue Pharma, L.P.Inventors: Ronald M. Burch, Paul D. Goldenheim, Richard S. Sackler
-
Patent number: 8685995Abstract: Embodiments of the invention provide methods of treating a disorder or disease characterized by cellular proliferation and migration by co-administering a synergistically effective amount of an mTOR inhibitor and a ?-opioid receptor antagonist.Type: GrantFiled: March 20, 2009Date of Patent: April 1, 2014Assignee: The University of ChicagoInventors: Jonathan Moss, Patrick A. Singleton
-
Publication number: 20140086987Abstract: Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: Mallinckrodt LLCInventors: Jae Han Park, Tiffani Eisenhauer, Anish Dhanarajan, Vishal Gupta, Stephen Overholt
-
Publication number: 20140088132Abstract: Crystalline, anhydrous hydrochloride salts of 4,5?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one (oxymorphone) are disclosed and three polymorphic forms of these salts are reported. The invention further relates to a method for the production of such salts, a pharmaceutical composition comprising an effective amount of such a salt and such a salt as a medicament and for the treatment and/or prevention of pain.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: GRÜNENTHAL GMBHInventors: Andreas FISCHER, Dagmar PETERS-GROTH, Dagmar LISCHKE
-
Publication number: 20140088131Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.Type: ApplicationFiled: November 26, 2013Publication date: March 27, 2014Applicant: Titan Pharmaceuticals, Inc.Inventors: Rajesh A. Patel, Louis R. Bucalo
-
Publication number: 20140080855Abstract: The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I): wherein R2, R7, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: June 10, 2013Publication date: March 20, 2014Applicant: THERAVANCE, INC.Inventors: Daisuke Roland Saito, Daniel D. Long, Lan Jiang, Bryan Frieman
-
Publication number: 20140079780Abstract: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed.Type: ApplicationFiled: November 19, 2013Publication date: March 20, 2014Applicant: GRUENENTHAL GMBHInventors: Elisabeth ARKENAU MARIC, Johannes BARTHOLOMÄUS, Heinrich KUGELMANN
-
Publication number: 20140080857Abstract: Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administering the pharmaceutical formulations to patients in need of such treatment.Type: ApplicationFiled: August 13, 2013Publication date: March 20, 2014Applicant: Orexigen Therapeutics, Inc.Inventors: Anthony A. McKinney, Gary Tollefson, Simon Kwok-Pan Yau, Ronald S. Vladyka, Rick Soltero
-
Publication number: 20140079773Abstract: Provided herein is technology relating to liposomes and particularly, but not exclusively, to compositions of liposomes encapsulating a biologically active agent, methods of preparing liposomes encapsulating a biologically active agent, and uses of liposomes encapsulating a biologically active agent to treat a subject.Type: ApplicationFiled: September 18, 2013Publication date: March 20, 2014Inventors: Timothy D. Heath, Lisa Ann Krugner-Higby, Lesley J. Smith, Sheng Tu, Natasha Kalkhof, Rebekah Kay Franklin
-
Publication number: 20140080858Abstract: The invention relates to a form of administration which is secured against misuse and which is thermoformed without extrusion, comprising at least one synthetic or natural polymer having a resistance to breaking of at least 500 N in addition to one or several active ingredients with a misuse potential and, optionally physiologically compatible auxiliary substances. The invention also relates to a method for the production thereof.Type: ApplicationFiled: November 20, 2013Publication date: March 20, 2014Applicant: GRUENENTHAL GMBHInventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU MARIC
-
Publication number: 20140080854Abstract: The present invention provides a compound of formula I: wherein X?, R1, and R2 are as defined herein, and compositions thereof.Type: ApplicationFiled: May 2, 2013Publication date: March 20, 2014Applicant: WyethInventor: Wyeth
-
Publication number: 20140080856Abstract: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.Type: ApplicationFiled: August 13, 2013Publication date: March 20, 2014Applicant: THERAVANCE, INC.Inventors: Sean Dalziel, Leticia M. Preza, Miroslav Rapta, Pierre-Jean Colson
-
Publication number: 20140073664Abstract: The present invention is directed to a method of treating or preventing an addictive behavior in a subject, said method comprising administering to said subject an effective amount of a dopamine antagonist and a opiate receptor antagonist or a composition comprising same. Further provided are pharmaceutical compositions comprising, as active substances, at least one dopamine antagonist and at least one opiate receptor antagonist.Type: ApplicationFiled: September 12, 2013Publication date: March 13, 2014Inventors: Jia Bei Wang, Sarah Sushchyk
-
Publication number: 20140072644Abstract: The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. The object of the present invention is to prevent solid oral drugs from being misappropriated for any use other than the therapeutic use(s) officially approved by the competent public health authorities. In other words, the object is to avoid the voluntary or involuntary misuse of solid oral drugs. The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the AP it comprises is contained in coated microparticles for modified release of the AP, and in that the coated microparticles of AP have a coating layer (Ra) which assures the modified release of the AP and simultaneously imparts crushing resistance to the coated microparticles of AP so as to avoid misuse.Type: ApplicationFiled: November 15, 2013Publication date: March 13, 2014Applicant: FLAMEL TECHNOLOGIESInventors: Florence Guimberteau, Frederic Dargelas
-
Publication number: 20140066467Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.Type: ApplicationFiled: August 21, 2013Publication date: March 6, 2014Applicant: The University of ChicagoInventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G.N. Garcia, Chun-Su Yuan
-
Publication number: 20140066471Abstract: Disclosed is an external preparation composition having good transdermal absorbability. An external preparation composition having excellent transdermal absorbability can be produced by dissolving a medicinal substance or a salt thereof in a fatty acid-based ionic liquid to form a composite ionic composition of the medicinal substance. The external preparation composition can be used as a liquid preparation, an ointment, a cream, a plaster or the like, and enables to provide a preparation having excellent transdermal absorbability.Type: ApplicationFiled: November 6, 2013Publication date: March 6, 2014Applicant: MEDRX CO., LTD.Inventors: Toshikazu YAMAGUCHI, Kenta KAWAI, Katsuhiro YAMANAKA, Noboru TATSUMI
-
Publication number: 20140057933Abstract: The present invention relates to an opioid controlled release oral dosage form comprising at least one opioid for the manufacture of a medicament to treat patients with Chronic Obstructive Pulmonary Disease (COPD).Type: ApplicationFiled: July 19, 2013Publication date: February 27, 2014Applicant: Euro-Celtique S.A.Inventors: Wolfgang FLEISCHER, Karen REIMER, Petra LEYENDECKER
-
Publication number: 20140057934Abstract: Methylnaltrexone nasal formulations are discloses which provide improved bioavailability over oral dosage forms and improved patient compliance over injectable dosage forms. Also disclosed are methods of making the nasal formulations and methods of using, specifically to treat the side effects of opioid drug use, such as constipation, and other indications.Type: ApplicationFiled: August 21, 2013Publication date: February 27, 2014Applicant: AptaPharma Inc.Inventor: Siva Rama K. Nutalapati
-
Publication number: 20140056979Abstract: The present invention relates to pharmaceutical multilayer dosage forms, for example to a tamper resistant dosage form comprising a first layer comprising an active agent and a second layer not comprising said active agent, and processes of manufacture, uses, and methods of treatment thereof providing essentially zero order release.Type: ApplicationFiled: March 22, 2012Publication date: February 27, 2014Applicant: Purdue Pharma L.P.Inventor: Haiyong Hugh Huang
-
Publication number: 20140056975Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated.Type: ApplicationFiled: November 4, 2013Publication date: February 27, 2014Applicant: Alpharma Pharmaceuticals LLCInventors: Alfred Liang, Francis Joseph Matthews, Garth Boehm, Lijuan Tang, Frank Johnson, Joseph Stauffer
-
Patent number: 8658198Abstract: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.Type: GrantFiled: March 13, 2013Date of Patent: February 25, 2014Assignee: Orexo ABInventor: Anders Pettersson
-
Publication number: 20140052051Abstract: Disclosed are a patch, system, and method for delivery of a permeant composition into a subject via at least one formed pathway through a biological membrane of the subject. The patch comprises a matrix, at least one hydrophilic permeant disposed within the matrix, wherein at least a portion of the permeant can dissolve in biological moisture received from the subject, and at least one permeability enhancer disposed within the matrix. Also disclosed are systems and methods for delivery of a permeant composition into a subject via at least one formed pathway through a skin layer of the subject.Type: ApplicationFiled: October 28, 2013Publication date: February 20, 2014Applicant: NITTO DENKO CORPORATIONInventors: FRANK TAGLIAFERRI, ALAN SMITH, DAVID ENSCORE, GAURAV TOLIA, MIREK BAUDYS
-
Publication number: 20140050787Abstract: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse.Type: ApplicationFiled: October 24, 2013Publication date: February 20, 2014Applicant: Egalet Ltd.Inventors: Peter Holm Tygesen, Jan Martin Oevergaard, Karsten Lindhardt, Louise Inoka Lyhne-Iversen, Martin Rex Olsen, Anne-Mette Haahr, Jocob Aas Hoeilund-Jensen, Pernille Kristine Hoeyrup Hemmingsen
-
Patent number: 8653271Abstract: The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist.Type: GrantFiled: October 18, 2007Date of Patent: February 18, 2014Assignee: University of Kentucky Research FoundationInventors: Audra L. Stinchcomb, Peter A. Crooks, Mohamed O. Hamad, Paul K. Kiptoo
-
Patent number: 8653065Abstract: A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.Type: GrantFiled: April 11, 2012Date of Patent: February 18, 2014Assignee: Pisgah Laboratories, Inc.Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
-
Publication number: 20140045876Abstract: The present invention provides a process for preparing an oxycodone acid adduct, said process comprising hydrogenating an aqueous solution of 14-hydroxycodeinone and an acid to form a solution of the oxycodone acid adduct, wherein the hydrogenation is carried out at one or more temperatures greater than ambient temperature in the presence of a hydrogenation catalyst and hydrogen gas, wherein the solution of oxycodone acid adduct comprises 6?-oxycodol in an amount ?about 0.800 area % as determined by HPLC.Type: ApplicationFiled: August 2, 2013Publication date: February 13, 2014Applicant: JOHNSON MATTHEY PUBLIC LIMITED COMPANYInventors: NICOLAS ARCHER, MAUREEN YOUNG, TIMOTHY DAVIES, AMY PRICE, MICHAEL BEASE, BARBARA JAMIESON, EWART GRANT, BRIAN HEINRICH, SAROOP MATHARU
-
Publication number: 20140044782Abstract: Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.Type: ApplicationFiled: October 21, 2013Publication date: February 13, 2014Applicant: ALZA CORPORATIONInventors: Evangeline Cruz, Atul D. Ayer, Brenda J. Pollock, Carmelita Garcia, Sherry Li, Alfredo M. Wong, Lawrence G. Hamel, Cheri Enders Klein, Yihong Qiu, Ye Huang
-
Publication number: 20140045801Abstract: The present invention relates to a method for the treatment and prevention of cluster headaches and migraines using the transdermal administration of pramipexole.Type: ApplicationFiled: August 9, 2012Publication date: February 13, 2014Applicant: MYLAN INC.Inventor: David Thomas Rossi
-
Publication number: 20140045877Abstract: The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner.Type: ApplicationFiled: October 18, 2013Publication date: February 13, 2014Applicant: Purdue Pharma L.P.Inventors: Bianca BRÖGMANN, Silke MÜHLAH, Christof SPITZLEY
-
Publication number: 20140045878Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.Type: ApplicationFiled: October 18, 2013Publication date: February 13, 2014Applicant: Euro-Celtique S.A.Inventors: Bianca BRÖGMANN, Silke MÜHLAH, Christof SPITZLEY
-
Patent number: 8647667Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.Type: GrantFiled: May 24, 2013Date of Patent: February 11, 2014Assignee: Purdue Pharma, L.P.Inventors: Benjamin Oshlack, Hua-Pin Huang, John K. Masselink, Alfred P. Tonelli
-
Publication number: 20140037729Abstract: The present invention provides a pharmaceutical dosage form comprising an opioid agonist and an opioid antagonist for use in the treatment of Parkinson's disease. The present invention also refers to the use of an opioid agonist and an opioid antagonist in such a dosage form.Type: ApplicationFiled: December 27, 2011Publication date: February 6, 2014Applicant: Euro-Celtique, S.A.Inventors: Michael Hopp, Claudia Trenkwalder
-
Publication number: 20140037727Abstract: A medicament tablet containing paracetamol (acetaminophen) as the (or an) active ingredient, and an encapsulated flavorant. The tablet may be swallowed in tablet form or may be dissolved or dispersed in water to form a palatable drink.Type: ApplicationFiled: October 8, 2013Publication date: February 6, 2014Applicant: Reckitt Benckiser Healthcare (UK) LimitedInventor: Paul Frederick Field